Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
GVR35
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "GVR35" in MCE Product Catalog:
Research Areas:
GPR35 agonist 2 (compound 11) is a potent agonist of GPR35, with EC50s of 26 and 3.2 nM in the β-arrestin and Ca 2+ release assay, respectively .
Research Areas:
GPR35 agonist 1 (compound 50) is a potent and specific G protein-coupled receptor-35 (GPR35)/CXCR8 agonist with an EC50 of 5.8 nM, displays good agentgability .
GPR35 agonist 4 (compound 10) is a potent GPR35 agonist with an pEC50 of 5.86. GPR35 agonist 4 shows high potency human and rat GPR35. Mutation of arginine 3.36 eliminates agonist function of GPR35 agonist 4 .
Cat. No.: HY-169302
CAS No.: 2855918-34-0
GPR35 activator-1 (example 5) is a potent GPR35 activator with a Ki of 0.08 nM for human GPR35 .
Target:
GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50value of 1.4 μM. GPR35 agonist 3 can be used for the research of various diseases, such as gastric cancer, type 2 diabetes, cardiovascular diseases, immune system and peripheral nervous system .
GPR35 agonist 5 (3,5-dinitro-bisphenol A; compound 6) is a weak GPR35 agonist. GPR35 agonist 5 arrests CHO-S cells at the G1/Gophase .
Cat. No.: HY-169301
CAS No.: 2994189-01-2
Gpr35 modulator 1 (compound 1-18) is a potent modulator of Gpr35, with the IC50 of ≤ 100 nM in HEK293 cells stably transfected with human GPR35 .
Cat. No.: HY-169303
CAS No.: 3049339-96-7
Target:
Research Areas:
Gpr35 modulator 2 (compound 52) is a GPR35 modulator. Gpr35 modulator 2 can be used for the study of a various GPR35-related disorders .
Cat. No.: HY-169304
CAS No.: 3055887-18-5
Target:
Research Areas:
Gpr35 modulator 3 (Example 105) is a Gpr35 modulator with an IC50 < 1 μM. Gpr35 modulator 3 can be used in the study of proliferative, immune, and inflammatory .
Cat. No.: HY-RS05706
Target:
Research Areas:
Gpr35 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gpr35 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS05705
Target:
Research Areas:
GPR35 Human Pre-designed siRNA Set A contains three designed siRNAs for GPR35 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS05707
Target:
Research Areas:
Gpr35 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gpr35 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-187384
Target:
Research Areas:
GPR35 agonist 7 is a selective GPR35 agonist, with an EC50 of 0.030 μM for hGPR35 and an EC50 of 0.021 μM for mGPR35. GPR35 agonist 7 reduces lipid accumulation. In a high-fat diet-induced MASH mouse model, GPR35 agonist 7 improves hepatic steatosis, corrects lipid metabolism disorders, alleviates hepatic inflammation and attenuates hepatic fibrosis. GPR35 agonist 7 can be used for the research of metabolic dysfunction-associated steatohepatitis .
Cat. No.: HY-187385
Target:
Research Areas:
GPR35 agonist 8 is a cross-species, highly potent GPR35 agonist (human EC50: 12 nM; murine EC50: 2 nM). GPR35 agonist 8 reduces lipid accumulation, ameliorates lipid metabolism disorders, alleviates hepatic inflammation and liver fibrosis, and relieves hepatic steatosis. GPR35 agonist 8 can be used for research on metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis .
Cat. No.: HY-W1058476
CAS No.: 1443367-20-1
Research Areas:
GPR35 agonist 6 is a potent and selective agonist targeting GPR35, with an EC50 of 12.1 nM against human GPR35. GPR35 agonist 6 activates the human splice variant GPR35b with comparable efficacy, showing an EC50 of 22.1 nM. GPR35 agonist 6 also exhibits weak GPR55 antagonistic activity, with an IC50 of 21.7 μM, and its agonistic activity towards GPR35 is significantly stronger than its antagonistic activity towards GPR55. GPR35 agonist 6 initiates GPR35 downstream signaling by inducing β-arrestin recruitment. GPR35 agonist 6 is used to investigate GPR35-mediated diseases, such as gastrointestinal lesions and gastric cancer .
Cat. No.: HY-P702306
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GPR35; Kynurenic Acid Receptor; G Protein-Coupled Receptor 35; KYNA Receptor; G-Protein Coupled Receptor 35
Species:
Human
Source:
E. coli Cell-free
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
